SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — Wilma Rudolph — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientWilma Rudolph
Date of birth1940-06-23
IdentifiersMRN HR-ML036-SYN-TD; SSN (made up) 000-36-5170
Document date1994-10-09
AuthorGloria Haynes-Whitaker, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

MRI result after chemoradiation and the first day of adjuvant temozolomide. [S]

History of Present Illness

Ms. Rudolph returns four weeks after the end of radiotherapy. The MRI two days ago shows thin, smooth enhancement along the edge of the resection cavity and no new or nodular enhancement, with less swelling than after surgery. Her energy has improved over the past two weeks and she is working half days. The scalp has healed. She saw the palliative care team eleven days ago, talked through her symptoms, her understanding of the illness and what matters most to her, and completed an advance directive naming a health care agent. The tumor-treating fields device was fitted yesterday and she wore it overnight. She has had no headache, seizure, change in speech, weakness or fall. She has had no thoughts of self-harm. [S]

ElementDetail
MRITreatment-related change only; no progression (RANO 2.0)
EnergyImproving; half days at work
Palliative careSeen eleven days ago; advance directive completed
TodayAdjuvant temozolomide cycle 1, day 1; tumor-treating fields started

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired in the afternoons, less than before; no fever
GastrointestinalNegativeNo nausea, vomiting or constipation
IntegumentaryNegativeScalp healed; no redness under the new arrays this morning
NeurologicalNegativeNo headache, seizure, speech change or weakness
Hematologic and lymphaticNegativeNo bruising or bleeding
RespiratoryNegativeNo cough or breathlessness
PsychiatricNegativeMore hopeful; PHQ-9 6; no thoughts of self-harm

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a dayTwo tablets every 6 hours as neededOral route1994-06-29activeS
Dexamethasone 4 mg oral tablet, one tablet twice a day with food, for symptomatic vasogenic edema, until surgeryOne tablet twice a day with breakfast and lunchOral route1994-06-30 to 1994-07-08completedS
Famotidine 20 mg oral tablet, one tablet twice a day while taking dexamethasoneOne tablet twice a dayOral route1994-06-30 to 1994-08-12completedS
Dexamethasone 2 mg oral tablet, one tablet twice a day after surgery, taperingOne tablet twice a dayOral route1994-07-10 to 1994-07-29completedS
Dexamethasone 2 mg oral tablet: one tablet daily for one week, then half a tablet daily for one week, then stopOne tablet daily for a week, then half a tablet daily for a weekOral route1994-07-29 to 1994-08-12completedS
Temozolomide 140 mg oral capsule, 140 mg (75 mg/m2) by mouth daily at bedtime on an empty stomach, seven days a week for 42 days from the first day of radiotherapyOnce daily at bedtime, seven days a week, for 42 daysOral route1994-08-03 to 1994-09-13completedS
Sulfamethoxazole 800 mg and trimethoprim 160 mg oral tablet, one tablet three times a week (Monday, Wednesday and Friday) to prevent Pneumocystis pneumoniaOne tablet on Monday, Wednesday and FridayOral route1994-08-03activeS
Ondansetron 8 mg oral tablet, one tablet 30 to 60 minutes before each temozolomide dose, and every 8 hours as needed for nauseaBefore each temozolomide dose; every 8 hours as neededOral route1994-08-03activeS
Temozolomide 140 mg oral capsule, 280 mg (150 mg/m2) by mouth at bedtime on days 1 to 5 of each 28-day cycle, adjuvant cycle 1 of 6Two capsules once daily at bedtime on days 1 to 5 of each 28-day cycleOral route1994-10-09activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1994-10-09Body height180cmS
1994-10-09Body weight66.6kgS
1994-10-09Body mass index (BMI) [Ratio]20.6kg/m2S
1994-10-09Systolic blood pressure120mm[Hg]S
1994-10-09Diastolic blood pressure76mm[Hg]S
1994-10-09Heart rate74/minS
1994-10-09Respiratory rate14/minS
1994-10-09Body temperature36.6CelS
1994-10-09Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1994-10-09Hemoglobin [Mass/volume] in Blood12.2g/dL12-15.5 g/dLNormalS
1994-10-09Leukocytes [#/volume] in Blood by Automated count4.410*3/uL4-11 10*3/uLNormalS
1994-10-09Neutrophils [#/volume] in Blood by Automated count2.910*3/uL1.5-7.7 10*3/uLNormalS
1994-10-09Lymphocytes [#/volume] in Blood by Automated count0.610*3/uL1-4 10*3/uLLowS
1994-10-09Platelets [#/volume] in Blood by Automated count16810*3/uL150-400 10*3/uLNormalS
1994-10-09Creatinine [Mass/volume] in Serum or Plasma0.81mg/dL0.59-1.04 mg/dLNormalS
1994-10-09Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1989)/1.73 sq M86mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1994-10-09Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-35 U/LNormalS
1994-10-09Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L8-35 U/LNormalS
1994-10-09Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
1994-10-09Glucose [Mass/volume] in Serum or Plasma91mg/dL70-99 mg/dLNormalS
1994-10-09Karnofsky Performance Status score80{score}S
1994-10-09Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S

Physical Exam

Vital signs recorded on 1994-10-09; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 66.6 kg; blood pressure 120/76, pulse 74
HeadScalp shaved for the arrays; skin intact; radiation dermatitis resolved
NeurologicalSpeech fluent; strength full in all four limbs; gait steady
ExtremitiesNo leg swelling or calf tenderness
PsychiatricEngaged and composed

Problems

ProblemClinical statusVerificationCodeProvenance
Three weeks of headaches on waking, with ten days of pauses in finding words and clumsiness of the right hand, in a previously well woman of 54: an intracranial lesion must be excluded. MRI of the brain with and without contrast booked for tomorrow morning, and neuro-oncology review bookedresolvedconfirmed R29.818S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded when the MRI showed a brain mass.
Left posterior frontal ring-enhancing mass, 3.8 cm, with central necrosis, surrounding edema and 5 mm midline shift, next to the language and motor areas; presumed high-grade glioma, with no primary cancer elsewhere on CT; tissue diagnosis pendingresolvedconfirmed D49.6S — Synthetic imaging diagnosis before surgery; superseded by the pathology.
Glioblastoma, IDH-wildtype, CNS WHO grade 4, left posterior frontal lobe, MGMT promoter methylated, after gross total resection of the enhancing tumor; synthetic modern detail linked to her publicly reported brain canceractiveconfirmed C71.1S — Synthetic histology, molecular result and location; brain cancer is documented as the cause of her death (D), and nothing more about it was made public.
Late effects of childhood poliomyelitis: paralysis of the left leg in early childhood, treated with a metal brace, a special shoe, massage and heat, with full recovery of walking by about age 12 and a later career as an Olympic sprinter; no new weakness, fatigue or pain now to suggest post-polio syndromeactiveconfirmed B91S — Documented childhood polio (D); the current absence of new symptoms is synthetic.
Vasogenic cerebral edema around the left frontal mass, with 5 mm midline shift, causing headache and contributing to the language and right-hand symptoms; treated with dexamethasoneresolvedconfirmed G93.6S — Synthetic finding on the first MRI.
Steroid-induced hyperglycemia on dexamethasone: random glucose 168 mg/dL, with an A1c of 5.6% before steroidsresolvedconfirmed R73.9S — Synthetic common effect of dexamethasone; resolved after the taper.
Lymphopenia from temozolomide, grade 2 (absolute lymphocytes 0.5 x 10^3/uL at the end of chemoradiation): Pneumocystis prophylaxis continues until recovery to grade 1 or betteractiveconfirmed D72.810S — Synthetic common effect of daily temozolomide with radiotherapy.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingMRI of the brain after chemoradiation (RANO 2.0)About four weeks after radiotherapy, then every two to three monthsUp to dateTwo days ago: treatment-related change, no progression; new baseline
ImagingNext MRI of the brainEvery two to three months during adjuvant treatmentDueAfter cycle 2
LaboratoryBlood count with neutrophils, lymphocytes and plateletsBefore each adjuvant cycle and on day 22Completed todayHemoglobin 12.2 g/dL, white cells 4.4, neutrophils 2.9, lymphocytes 0.6, platelets 168: cycle 1 can start
LaboratoryDay-22 blood countDay 22 of each adjuvant cycle, then weekly until neutrophils exceed 1.5DueBooked for the preventive visit three weeks from now
LaboratoryLiver tests (ALT, AST, bilirubin)Before each cycle and midway through cycle 1Completed todayALT 31, AST 27 U/L, bilirubin 0.5 mg/dL; the grade 1 rise has resolved
LaboratoryLiver tests midway through adjuvant cycle 1Midway through the first cycleDeferredA planned deviation: to spare her an extra trip, the mid-cycle liver tests will be drawn with the day-22 blood count, about a week after the label's midpoint. Today's liver tests are normal after a grade 1 rise. Outcome and action to be recorded at that draw
LaboratoryKidney function and glucoseEach visitCompleted todayCreatinine 0.81 mg/dL, eGFR 86; glucose 91 mg/dL
Medication safetyPneumocystis pneumonia prophylaxisUntil lymphopenia is grade 1 or betterCompleted todayContinues for lymphocytes 0.6
Medication safetyAntiemetic before temozolomideEach doseCompleted todayOndansetron before each bedtime dose
Self-managementTumor-treating fields: wear time and scalp careEach visit while in useCompleted todayStarted yesterday; at least 18 hours a day; shave and shift arrays at each change; report redness or blisters
ExaminationNeurologic examination (language, strength, gait)Each visitCompleted todayNo deficit
Medication safetySeizure history and antiseizure drug needEach visitNot indicatedNo seizure; no antiseizure drug
ExaminationSigns of leg clot or pulmonary embolismEach visitCompleted todayNone
SurveyPerformance status (Karnofsky)Each visitCompleted todayKarnofsky 80
ReferralPalliative careEarly and ongoingUp to dateSeen eleven days ago; advance directive completed; follow-up in two months
Self-managementFalls, leg strength and late effects of polioEach visitCompleted todayNo falls; legs strong; walking daily
SurveyDistress and depression screen (PHQ-9)At diagnosis, each treatment phase, and when symptoms changeCompleted todayPHQ-9 6; no thoughts of self-harm

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (2026); Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18(3):170-186 (PMID 33293629) (2021); Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996 (PMID 15758009) (2005); Stupp R, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma (EF-14). JAMA 2017;318(23):2306-2316 (PMID 29260225) (2017); Wen PY, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 2023 (PMID 37774317) (2023); TEMODAR (temozolomide) capsules, prescribing information (2026); Walbert T, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol 2021;23(11):1835-1844 (PMID 34174071) (2021); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024); Farbu E, et al. EFNS guideline on diagnosis and management of post-polio syndrome. Eur J Neurol 2006;13(8):795-801 (PMID 16879288) (2006); CMID: Clinical Monitoring Intelligence Database, depression monograph (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Temozolomide days 1 to 5 from tonight. Preventive visit and day-22 blood count with liver tests in three weeks. Neuro-oncology review and MRI after cycle 2. Call for fever, bruising, a seizure, headache, new weakness or scalp blisters. Next scheduled visit 1994-10-29: periodic adult preventive visit. [S]